Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453368) titled 'Orelabrutinib in the Treatment of Relapsed/Refractory AIHA' on March 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking Union Medical College Hospital

Condition: Autoimmune Hemolytic Anemia (AIHA)

Intervention: Drug: Orelabrutinib-50 Drug: Orelabrutinib-100

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 1, 2026

Target Sample Size: 50

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07453368 ...